

### PERSONAL INFORMATION **Guy Berchem**

#### WORK EXPERIENCE

---

- May 2020- Present **Professor of Medical Oncology**  
University of Luxembourg (Luxembourg)  
In charge specialization curriculum in Medical Oncology
- February 1999- Present **Medical Oncologist & Director of research**  
Centre Hospitalier de Luxembourg (Luxembourg)  
Head of Hemato-Oncology
- July 2019- Present **Ass Medical Director Luxembourg Institute of Health**  
Luxembourg Institute of Health (Luxembourg)
- January 2004-July 2019 **Head of LHCE research lab**  
Luxembourg Institute of Health (Luxembourg)  
Cell biology, cell death, immunotherapy, biomarkers research
- October 1996-December 1998 **Medical oncologist**  
Bordet Institute Cancer center, Brussels (Belgium)
- October 1996-December 1998 **Chargé de recherches FNRS (Belgian National Research Fund)**  
Bordet Institute Cancer center, Brussels (Belgium)
- July 2016- Present **President**  
Luxembourg National Cancer Institute (Luxembourg)

#### EDUCATION AND TRAINING

---

- September 2011-December 2014 **PhD title**  
Université Paris Sud, Orsay (Paris XI) (France)
- October 1983-July 1990 **MD Title : Docteur en Médecine Chirurgie et Accouchements**  
Université Libre de Bruxelles (Belgium)
- October 1990-July 1996 **Medical oncology and Internal medicine**  
Université Libre de Bruxelles (Belgium)
- September 1993-August 1995 **Postdoctoral fellowship**  
Lombardi Cancer Center, Georgetown University, Washington DC (United States)

#### ADDITIONAL INFORMATION

---

- Expertise** Medical ONcologist specializing in Lung cancer, GI oncology and neurooncology.  
Cell biology, cell death, immunotherapy, biomarkers research
- Active participation ac PI and coPI in numerous clinical studies  
In the domains of lung cancer, prostate cancer, bladder cancer, melanoma, Myeloma etc

## Publications

101. Janji B, Hasmim M, Parpal S, Berchem G, Noman MZ. Firing up the cold tumors by targeting Vps34. *Oncoimmunology*. 2020 Aug 31;9(1):1809936. 100. Janji B, Hasmim M, Parpal S, De Milito A, Berchem G, Noman MZ. Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34. *Autophagy*. 2020 Sep 5:1-2.

99. Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, Müller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G. Oncological care organisation during COVID-19 outbreak. *ESMO Open*. 2020 Aug;5(4) 98. El-Khoury V, Schritz A, Kim SY, Lesur A, Sertamo K, Bernardin F, Petritis K, Pirrotte P, Selinsky C, Whiteaker JR, Zhang H, Kennedy JJ, Lin C, Lee LW, Yan P, Tran NL, Inge LJ, Chalabi K, Decker G, Bjerkvig R, Paulovich AG, Berchem G, Kim YJ. Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection. *Cancers (Basel)*. 2020 Jun 19;12(6):1629. 97. Muhammad Zaeem Noman, Santiago Parpal, Kris Van Moer, Malina Xiao, Yasmin Yu, Jenny Viklund, Angelo De Milito, Meriem Hasmim, Martin Andersson; Ravi K Amaravadi, Jessica Martinsson, Bassam Janji\* and Guy Berchem\* Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy *Science Adv*. 2020 Apr 29;6(18) 96. Boeckx B, Bahadur Shahi R, Smeets D, De Brakeleer S, Decoster L, Van Brussel T, Galdermans D, Vercauter P, Decoster L, Alexander P, Berchem G, Ocak S, Vuylsteke P, Deschepper K, Lambrechts M, Cappoen N, Teugels E, Lambrechts D, De Greve J. The genomic landscape of non-small cell lung carcinoma in never smokers. *Int J Cancer*. 2019 Nov 19. 95. Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G\*, Janji B\*. Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. *Cells*. 2019 Sep 14;8(9) 94. Ries M, Khreish F, Berchem G, Ezziddin S. Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer. *Clin Nucl Med*. 2019 Jul 5. 93. Lequeux A, Noman MZ, Xiao M, Sauvage D, Van Moer K, Viry E, Bocci I, Hasmim M, Bosseler M, Berchem G, Janji B. Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. *Cancer Lett*. 2019 Aug 28;458:13-20. 92. Kindt N, Descamps G, Lechien JR, Rimmelink M, Colet JM, Wattiez R, Berchem G, Journe F, Saussez S. Involvement of HPV Infection in the Release of Macrophage Migration Inhibitory Factor in Head and Neck Squamous Cell Carcinoma. *J Clin Med*. 2019 Jan 10;8(1). 91. Xiao M, Noman MZ, Menard L, Chevigne A, Szpakowska M, Bosseler M, Ollert M, Berchem G, Janji B. Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots. *Crit Rev Oncog*. 2018;23(5-6):321-332. 90. Wierz M, Janji B, Berchem G, Moussay E, Paggetti J. High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia. *Oncoimmunology*. 2018 May 24;7(8) 89. Noman MZ, Paggetti J, Moussay E, Berchem G, Janji B. Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target. *Oncoimmunology*. 2018 Apr 25;7(8) 88. Al Absi A, Wurzer H, Guerin C, Hoffmann C, Moreau F, Mao X, Brown-Clay J, Petrolli R, Casellas CP, Dieterle M, Thiery JP, Chouaib S, Berchem G, Janji B, Thomas C. Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity. *Cancer Res*. 2018 Oct 1;78(19):5631-5643. 87. Hoffmann C, Mao X, Brown-Clay J, Moreau F, Al Absi A, Wurzer H, Sousa B, Schmitt F, Berchem G, Janji B, Thomas C. Hypoxia promotes breast cancer cell invasion through HIF-1-mediated up-regulation of the invadopodial actin bundling protein CSRP2. *Sci Rep*. 2018 Jul 5;8(1):10191. 86. Janji B, Berchem G, Chouaib S. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity. *Front Immunol*. 2018 Apr 25;9:887. 85. Bosseler M, Marani V, Broukou A, Lequeux A, Kaoma T, Schlessler V, François JH, Palissot V, Berchem GJ, Aouali N, Janji B. Inhibition of HIF1-Dependent Upregulation of Phospho-I-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy. *Int J Mol Sci*. 2018 May 23;19(6) 84. Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H. The clinical impact of using complex molecular profiling strategies in routine oncology practice. *Oncotarget*. 2018 Apr 17;9(29):20282-20293 83. Noman MZ, Van Moer K, Marani V, Gemmill RM, Tranchevent LC, Azaaje F, Muller A, Chouaib S, Thiery JP, Berchem G\*, Janji B\*. CD47 is a direct target of SNAIL and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. *Oncoimmunology*. 2018 Feb 15;7(4):e1345415 82. Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem G, Janji B, Guérin C, Paggetti J, Moussay E. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. *Blood*. 2018 Apr 5;131(14):1617-1621 81. Wierz M, Pierson S, Chouha N, Désaubry L, François JH, Berchem G, Paggetti J, Moussay E. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells ex vivo but fails to prevent leukemia development in a murine model.

Haematologica. 2018 Jan 5 80. Noman MZ, Berchem G, Janji B. Targeting autophagy blocks melanoma growth by bringing natural killer cells to the tumor battlefield. *Autophagy*. 2018 Mar 11;1:1-3 79. Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem G, Janji B, Guérin C, Paggetti J, Moussay E. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. *Blood*. 2018 Feb 13 78. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Mgrditchian T, Arakelian T, Paggetti J, Noman MZ, Viry E, Moussay E, Van Moer K, Kreis S, Guerin C, Buart S, Robert C, Borg C, Vielh P, Chouaib S, Berchem G\*, Janji B\*. *Proc Natl Acad Sci U S A*. 2017 Oct 31;114(44) 77. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Giuliani M, Janji B, Berchem G. *Oncotarget*. 2017 Feb 9. 76. Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet. Viry E, Noman MZ, Arakelian T, Lequeux A, Chouaib S, Berchem G, Moussay E, Paggetti J, Janji B. *Front Oncol*. 2016 Nov 18;6:246 75. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy. Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D, Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S. *Oncologist*. 2016 Dec;21(12):1416-e17 74. Case Report Primary Spinal Lymphoma Meyers T, De Wilde S, Berchem G *Bull Soc Sci Med Grand Duche Luxemb*. 2016;(1):91-95 73. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Bennett CW, Berchem G, Kim YJ, El-Khoury V. *Oncotarget* 2016 Aug 30. doi: 10.18632/oncotarget.11717. [Epub ahead of print] 72. A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B-cells. Medves S, Auchter M, Chambeau L, Gazzo S, Poncet D, Grangier B, Verney A, Moussay E, Ammerlaan W, Brisou G, Morjani H, Géli V, Palissot V, Berchem G, Salles G, Wenner T. *Br J Haematol*. 2016 Jul;174(1):57-70. 71. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF- and miR23a transfer Berchem G, Noman MZ, Bosseler M, Paggetti J, Baconnais S, Le Cam E, Nanbakhsh A, Moussay E, Mami-Chouaib F, Janji B, Chouaib S. *Oncoimmunology*. 2015 Jun 24;5(4) 70. Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E. *PLoS One*. 2016 Mar 31;11(3) 69. The multifaceted role of autophagy in tumor evasion from immune surveillance. Janji B, Viry E, Moussay E, Paggetti J, Arakelian T, Mgrditchian T, Messai Y, Noman MZ, Van Moer K, Hasmim M, Mami-Chouaib F, Berchem G, Chouaib S. *Oncotarget*. 2016 Feb 20. doi: 10.18632/oncotarget.7540 68. CRP2, a new invadopodia actin bundling factor critically promotes breast cancer cell invasion and metastasis. Hoffmann C, Mao X, Dieterle M, Moreau F, Al Absi A, Steinmetz A, Oudin A, Berchem G, Janji B, Thomas C. *Oncotarget*. 2016 Feb 11. doi: 10.18632/oncotarget.7327 67. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Klionsky DJ et al. (Berchem G) *Autophagy*. 2016 Jan 2;12(1):1-222. 66. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. *Sci Rep*. 2016 Jan 20;6:19529. 65. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a transfer. Berchem G, Noman MZ, Bosseler M, Paggetti J, Baconnais S, Le Cam E, Nanbakhsh A, Moussay E, Mami-Chouaib F, Janji B, Chouaib S. *Oncoimmunology*, 2016 In Press 64. MiR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function. Noman MZ, Janji B, Berchem G, Chouaib S. *Cancer Lett*. 2015 Oct 30. pii: S0304-3835(15)00657-6. 63. MiR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function. Noman MZ, Janji B, Berchem G, Chouaib S. *Cancer Lett*. 2015 Oct 30. pii: S0304-3835(15)00657-6. 62. Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays. Kim YJ, Gallien S, El-Khoury V, Goswami P, Sertamo K, Schlessner M, Berchem G, Domon B. *Proteomics*. 2015 Jul 16. 61. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, Kim YJ, Adam J, Lichter P, Solary E, Berchem G, Moussay E. *Blood*. 2015 Jun 22. pii: blood-2014-12-618025. 60. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells. Aouali N, Broukou A, Bosseler M, Keunen O, Schlessner V, Janji B, Palissot V, Stordeur P, Berchem G. *PLoS One*. 2015 Jun 19;10(6):e0130339. 59. Screening protein isoforms predictive for cancer using immuno-affinity capture and fast LC-MS in PRM mode. Lesur A, Ancheva L, Kim YJ, Berchem G, van Oostrum J, Domon B. *Proteomics Clin Appl*. 2015 Feb 5. 58. Verification of the Biomarker Candidates for

Non-Small-Cell Lung cancer Using a Targeted Proteomics Approach. Kim YJ, Sertamo K, Pierrard MA, Mesmin C, Kim SY, Schlessner M, Berchem G, Domon B. *J Proteome Res.* 2015 Jan 16. 57.

Editorial to 125 years edition anniversary of the Société des Sciences Médicales du Grand Duché de Luxembourg Berchem G. *Bull Soc Sci Med Grand Duché Luxemb.* 2014;7-8. 56.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. M, Qian X, Domine M, Rosell R et al. for the BREC Investigators. (G Berchem) *Ann Oncol.* 2014 Nov;25(11):2147-55. 55.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. (G Berchem) *N Engl J Med.* 2014 Dec 4;371(23):2167-77. 54.

Autophagy: An adaptive metabolic response to stress shaping the antitumor immunity. Viry E, Paggetti J, Baginska J, Mgrditchian T, Berchem G, Moussay E, Janji B. *Biochem Pharmacol.* 2014 Nov 1;92(1):31-42. 53.

BAG6/BAT3 modulates autophagy by affecting EP300/p300 intracellular localization. Sebti S, Prébois C, Pérez-Gracia E, Bauvy C, Desmots F, Pirot N, Gongora C, Bach AS, Hubberstey AV, Palissot V, Berchem G, Codogno P, Linares LK, Liaudet-Coopman E, Patingre S. *Autophagy* 2014 May 15;10(7) 52.

BAT3 modulates p300-dependent acetylation of p53 and autophagy-related protein 7 (ATG7) during autophagy. Sebti S, Prébois C, Pérez-Gracia E, Bauvy C, Desmots F, Pirot N, Gongora C, Bach AS, Hubberstey AV, Palissot V, Berchem G, Codogno P, Linares LK, Liaudet-Coopman E, Patingre S. *Proc Natl Acad Sci U S A.* 2014 Mar 3 51.

Bronchial airway gene expression in smokers with lung or head and neck cancer. Van Dyck E, Nazarov PV, Muller A, Nicot N, Bosseler M, Pierson S, Van Moer K, Palissot V, Mascaux C, Knolle U, Ninane V, Nati R, Bremnes RM, Vallar L, Berchem G\*, Schlessner M\*. *Cancer Med.* 2014 Feb 4. 50.

Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. El-Khoury V, Pierson S, Szwarcbart E, Brons NH, Roland O, Cherrier-De Wilde S, Plawny L, Van Dyck E, Berchem G. *Leukemia.* 2014 Jan 14. 49.

The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity. Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, Janji B. *Front Immunol.* 2013 Dec 25;4:490. 48.

Autophagic degradation of GZMB/granzyme B: A new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis. Viry E, Baginska J, Berchem G, Noman MZ, Medves S, Chouaib S, Janji B. *Autophagy.* 2013 Nov 15;10(1). 47.

Granzyme B degradation by autophagy decreases tumor cell susceptibility to Natural Killer-mediated lysis under hypoxia autophagy degrades NK-derived granzyme B. Joanna Baginska , Elodie Viry\* , Guy Berchem\* , Aurelie Poli , Muhammad Zaeem Noman , Kris van Moer , Sandrine Medves , Jacques Zimmer , Anais Oudin , Simone P Niclou , R. Chris Bleackley , Ing Swie Goping , Salem Chouaib , Bassam Janji *PNAS* 2013 Oct 22;110(43):17450-5. Epub 2013 Oct 7 46.

Giant melanoma of the scalp: Case report. Calteux N, Berchem G, Schmid N, Nebendahl J, Fischer G. *Bull Soc Sci Med Grand Duché Luxemb.* 2013;(1):40-6. 45.

Stromal cell-induced miRNA alteration in chronic lymphocytic leukaemia: how a minute and unavoidable cell contamination impairs miRNA profiling. Paggetti J, Berchem G, Moussay E. *Leukemia.* 2013 Feb 14. 44.

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. Gäbler K, Rolvering C, Kaczor J, Eulenfeld R, Maendez SA, Berchem G, Palissot, V, Behrmann I, Haan C. *J Cell Mol Med.* 2013 Jan 10. 43.

Hypoxia-induced autophagy: A new player in cancer immunotherapy? Noman MZ, Janji B, Berchem G, Mami-Chouaib F, Chouaib S. *Autophagy.* 2012 Apr 1;8(4). 42.

Lung cancer statistics in Luxembourg from 1981 to 2008. Thill PG, Goswami P, Berchem G, Domon B. *Bull Soc Sci Med Grand Duché Luxemb.* 2011;(2):43-55. 41.

7-year results of cell therapy in patients with severe ischemic cardiomyopathy. Ekosso L, Delagardelle C, Berchem G, Beissel J, Wagner DR. *Bull Soc Sci Med Grand Duché Luxemb.* 2011;(2):35-42. 40.

The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. Metzger B, Chambeau L, Begon DY, Faber C, Kayser J, Berchem G, Pauly M, Boniver J, Delvenne P, Dicato M, Wenner T. *BMC Med Genet.* 2011 Oct 25;12(1):144. 39.

Blocking hypoxia-induced autophagy in tumors restores cytotoxic T cell activity and promotes regression. Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, Chouaib S. *Cancer Res.* 2011 Aug 2. 38.

First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in Caucasian patients (pts) (NCT00339586)-FIELT study group. De Greve J, Van Meerbeeck JP, Vansteenkiste JF, Teugels E, Geers C, Meert A, Vuylsteke P, Focan CN, Canon J, Humblet Y, Berchem GJ, Colinet B, Galdermans D, Bosquée L, Dooms CA, Decoster L, Vermeij J, Dewaele A, Schallier DC. *J Clin Oncol.* 2011 May 20;29(15\_suppl):7597. 37.

The acquisition of resistance to TNFalpha in breast cancer cells is associated with constitutive activation of autophagy as revealed by a transcriptome analysis using a custom microarray. Moussay E, Kaoma T, Baginska J, Muller A, Van Moer K, Nicot N, Nazarov PV, Vallar L, Chouaib S, Berchem G, Janji B. *Autophagy.* 2011 Jul 1;7(7). 36.

MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukaemia.

Etienne Moussay\*, Kai Wang\*, Ji-Hoon Chob, Kris van Moer, Sandrine Pierson, Jérôme Paggetti, Petr V. Nazarov, Valérie Palissot, Leroy E. Hood, David J. Galas\*, Guy Berchem\* (\*contributed equally) Proc Natl Acad Sci U S A. 2011 Apr 1. 35. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia Etienne Moussay, Valérie Palissot, Laurent Vallar, Hélène A Poiriel, Thomas Wenner, Victoria El Khoury, Nasséra Aouali, Kris Van Moer, Bernadette Leners, François Bernardin, Arnaud Muller, Pascale Cornillet-Lefebvre, Alain Delmer, Caroline Duhem, Fernand Ries, Eric van Dyck, Guy Berchem Molecular Cancer, Mol Cancer. 2010 May 20;9:115. 34. A population based economic analysis of cross-border payments for fertility services in Luxembourg. Jones CA, Keith LG, Bocquet V, Arendt J, Smit J, Berchem G, Lair ML. J Exp Clin Assist Reprod. 2010 Oct 4;7:pii: 3. 33. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Victoria El Khoury, Etienne Moussay, Bassam Janji, Valérie Palissot, Nasséra Aouali, Nicolaas Brons, Kris Van Moer, Sandrine Pierson, Eric Van Dyck, Guy Berchem Mol Cancer Ther. 2010 May;9(5):1349-60. 32. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Hamai A, Benlalam H, Meslin F, Hasmim M, Carré T, Akalay I, Janji B, Berchem G, Noman MZ, Chouaib S. Tissue Antigens. 2010 Jan;75(1):1-8. 31. Challenges with advanced therapy medicinal products and how to meet them. The Committee for Advanced Therapies (CAT), Schneider CK, Salmikangas P, Jilma B, Flamion B, Todorova LR, Paphitou A, Haunerova I, Maimets T, Trouvin JH, Flory E, Tsiftoglou A, Sarkadi B, Gudmundsson K, O'Donovan M, Migliaccio G, Ancns J, Maulaitis R, Robert JL, Samuel A, Ovelgönne JH, Hystad M, Fal AM, Lima BS, Moraru AS, Turáni P, Zorec R, Ruiz S, Akerblom L, Narayanan G, Kent A, Bignami F, Dickson JG, Niederwieser D, Figuerola-Santos MA, Reischl IG, Beuneu C, Georgiev R, Vassiliou M, Pychova A, Clausen M, Methuen T, Lucas S, Schüssler-Lenz M, Kokkas V, Buzás Z, Macaleenan N, Galli MC, Lin A, Gulbinovic J, Berchem G, Frczek M, Menezes-Ferreira M, Vilceanu N, Hrubiko M, Marinko P, Timón M, Cheng W, Crosbie GA, Meade N, di Paola ML, Vandendriessche T, Ljungman P, D'Apote L, Oliver-Diaz O, Büttel I, Celis P. Nat Rev Drug Discov. 2010 Mar;9(3):195-201. 30. The actin filament cross-linker L-plastin confers resistance to TNF-alpha in MCF-7 breast cancer cells in a phosphorylation-dependent manner. Janji B, Vallar L, Al-Tanoury Z, Bernardin F, Vetter G, Schaffner-Reckinger E, Berchem G, Friederich E, Chouaib S. J Cell Mol Med. 2009 Oct 3 29. PPAR agonists potentiate the cytotoxic effect of Valproic acid in multiple myeloma cells. N Aouali, V Palissot, V El-Khoury, E Moussay, B Janji, S Pierson, N H.C. Brons, L Kellner, M Bosseler, K Van Moer, G Berchem Brit J of Haematol 2009 Dec147(5):662-71. 28. PCN158 Luxembourg lung cancer project: Potential clinical and economic impact of biomarker development in the diagnosis and treatment of single pulmonary nodules in Luxembourg. JJ Carlson, L Clarke, G Berchem, M Schlessler, J Nelson, SD Ramsey Value in Health (IF: 2.19). 01/2009; 12(7) 27. A case of acute haemolysis with 2 different multi target kinase inhibitors in a patient with RCC. G Berchem, S Dewilde, P Mahassen Bull Soc Sci Med Grand Duche Luxemb. 2009;(1): 7-10 26. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team (G Berchem) Lancet. 2009 May 2;373(9674):1525-31. 25. Valproate synergizes with nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. AB Bouzar, M Boxus, J Defoiche, G Berchem, D Macallan, R Pettengel, F Willis, A Burny, L Lagneaux, D Bron, B Chatelain, C Chatelain, L Willems. Brit Journ Hematol 2008; Jan;144(1):41-52. 24. Cell therapy for severe chronic heart failure: the Luxembourg experience. Rouy D, Lebrun F, Berchem G, Delagardelle C, Beissel J, Wagner DR. Biomed Mater Eng. 2008;18(1 Suppl):S27-31 23. Postsurgical surveillance: How intensive should it be? M. Dicato, S. Cherrier, E. Van Cutsem, G. Berchem. Current Colorectal Cancer Reports 2007; Fév; Vol 3, N°1, 3: 35-38 22. Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Schwartz, V. Palissot, N. Aouali, S. Wack, N.H.C. Brons, B. Leners, M. Bosseler, G. Berchem. Int J Oncol. 2007; Mar; 30(3):573-82 21. Improvement of exercise-induced cardiac deformation after cell therapy for severe chronic ischemic heart failure. F. Lebrun, G. Berchem, Ch. Delagardelle, J. Beissel, DR Wagner. J Card Fail 2006; Mar;12(2):108-13 21. Overexpression of both catalytically active and-inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity. M. Beaujouin, S. Baghdiguan, M. Glondu-Lassis, G. Berchem, E. Liaudet-Coopman. Oncogene. 2005 Dec 5 [Epub ahead of print] 20. From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells. V. Palissot, H. Morjani, F. Belloc, S. Cotteret, J. Dufer, G. Berchem. Int J Oncol. 2005 Mar;26(3):825-34 19. Comparison of standard PCR and the Light Cycler technique to determine the thrombophilic mutations: an efficiency and cost study. B. Schreoll-Metzger, M. Dicato, M. Bosseler, G. Berchem. Clin Chem Lab Med. 2003 Apr;41(4):482-5 18. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. G. Berchem, M. Glondu, M. Gleizes, J.P. Brouillet, F. Vignon, M. Garcia, E. Liaudet-Coopman.

Oncogene. 2002 Aug 29;21(38):5951-17. The biology of colorectal cancer. M. Dicato, G. Berchem, C. Duhem, F. Ries. *Semin Oncol.* 2000 Oct;27(5 Suppl 10):2-9 16. Clinical benefit from erythropoietin. M. Dicato, C. Duhem, G. Berchem, F. Ries. *Curr Opin Oncol.* 2000 Jul;12(4):297-302 15. Dépistage de la néoplasie bronchique M. Schlessler, G. Berchem, R. Nati. *Bull Soc Sci Med Grand Duché Luxemb.* 1999;(2):45-57 14. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. G. Berchem, M. Bosseler, N. Mine and B. Avalosse. *Anticancer Research*, 19, 535-40 1999 13. The aspirin metabolite salicylate inhibits breast cancer cell growth and their synthesis of osteoclastic cytokines Interleukins-6 and 11. Ch. Sotiriou, M. Lacroix, L. Lagneau, G. Berchem and J.-J. Body. *Anticancer Research*, 19, 2997-3006 1999 12. Androgens induce bcl-2 expression and confer chemotherapy-resistance by blocking apoptosis in LNCaP prostate cancer cells. G.J. Berchem., M.C. Bosseler, H.J. Voeller, and E.P. Gelmann. *Cancer Research*, 55: 735-738, (1995) 11. Resistance to Apoptosis and Upregulation of Bcl-2 in Benign Prostatic hyperplasia After Androgen Deprivation. Marina Cardillo\*, Guy Berchem\*, Mary Ann Tarkington, Stanislaw Krajewski, Maryla Krajewski, John Reed, Timothy Tehan, Louis Ortega, Janice Lage, and Edward P. Gelmann. *Journal of Urology*, 1997, vol 158, Iss1, pp 212-216 10. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. F. Czubayko, E. Liaudet-Coopman, Achim Aigner., Anne T. Tuveson, G. Berchem and A. Wellstein. *Nature Medicine*, (1997) Oct; 3(10): 1137-1140 9. Human melanoma angiogenesis and metastasis dependent on pleiotrophin. F. Czubayko, A.M. Schulte, G. Berchem and A. Wellstein. *Proc. Natl. Acad. Sci. USA* (1997) Vol. 93, (14753-8) 8. Cooperation of tgf a and c-myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis. L.T. Amundadottir, S.J. Nass, G. Berchem, M.D. Johnson and R.B. Dickson. *Oncogene* (1996) Aug 15;13(4):757-65 7. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. E. Liaudet-Coopman, G. Berchem, A. Wellstein. *Clinical Cancer Research* (1997) Vol. 3, 179-184 6. Epirubicin cardiotoxicity: A study comparing low versus high dose intensity per week schedules. G. Berchem, F. Ries, C. Duhem, M. Dicato, M. Keipes and Ch. Delagardelle. *Supportive Care Cancer* (1996) 4:308-312 5. Gestational trophoblastic diseases: an update on application of modern ancillary diagnostic modalities to diagnosis and treatment and review of new developments in molecular biology. J.M. Lage, A. Bagg, G. Berchem. *Current Opinion in Obstetrics & Gynecology* (1996) 8:79-82 4. La chémoprévention: une nouvelle stratégie de lutte contre le cancer du sein. G. Berchem, M. Dicato et F. Ries. *Bul. Soc. Sc. Med.* p.5 - No 1/1993 3. Calbindin D28k in rat gastrointestinal tract. G. Berchem, A. Résibois, R. Pochet and J.L. Pasteels. *Digestive Diseases and Sciences*, Vol. 34, No. 6 (1989) 2. Corrélation entre cervicographie et cytologie dans le dépistage des lésions cervicales. M. Coibion, G. Berchem, D. Hertens, J.M. Nogaret. *Gynécologie* (1991), 42 : 156-159 1. Dépistage du cancer du col utérin. La cervicographie a-t-elle sa place à côté du frottis cytologique ? M. Coibion, G. Berchem, A. Miloïu, I. Lorent, J.-L. Bonnal, Ch. Guenier, J.-M.. Nogaret. *Patient Care* 13, 7,56-59, (1990)

**Projects** Active participation ac PI and coPI in numerous clinical studies (>30)

In the domains of lung cancer, prostate cancer, bladder cancer, melanoma, Myeloma etc

**Memberships** Society memberships :

American Society of Clinical Oncology (ASCO) active member since 1994.

American Association of Cancer Research (AACR) since 1994.

American Association for the Advancement of Science (AAAS) since 1994.

Association belge pour l'étude du Cancer (ABEC) since 1997.

Société Luxembourgeoise d'Oncologie (SLO) Founding Member (2000)

president since 2001.

Scientific committees :

Member Scientific committee FNRS (Belgian National Research Fund) for televisive applications

Member of (CAT) committee for advanced therapeutics of EMEA (European Medicines Evaluation Agency) London

President scientific committee of (LNS) Laboratoire National de Santé du Grand Duché de Luxembourg

Other Relevant Information